Nafarelin
An FDA-approved GnRH agonist delivered intranasally — the only GnRH agonist in routine US nasal-spray practice — used for endometriosis and central precocious puberty.
What is Nafarelin?
Nafarelin is a synthetic nonapeptide GnRH superagonist (pGlu-His-Trp-Ser-Tyr-D-2-Nal-Leu-Arg-Pro-Gly-NH2) with a 3-(2-naphthyl)-D-alanine substitution at position 6 that confers both enhanced GnRH receptor binding potency (roughly 200-fold over native GnRH) and the unusual property of effective intranasal absorption. Originally developed by Syntex (subsequently acquired into Roche and now marketed in the US by Pfizer), nafarelin was FDA-approved as Synarel nasal spray in February 1990 for endometriosis and in 1992 for central precocious puberty. It is the only GnRH agonist routinely delivered intranasally in approved US clinical practice, which makes it a notable outlier within a therapeutic class otherwise dominated by intramuscular and subcutaneous depot injections.
What Nafarelin Is Investigated For
Nafarelin occupies a specific, well-evidenced niche within the GnRH agonist class: it is the only agent in routine US approved practice that is given as a twice-daily intranasal spray rather than as a depot injection. Its strongest evidence is in endometriosis, where multiple randomized controlled trials — including head-to-head comparisons against danazol and against leuprolide depot — established comparable symptom relief and disease suppression with a distinct side-effect and convenience profile. It is also FDA-approved and widely used for central precocious puberty in children, where the non-injectable delivery route can be meaningfully attractive to families, and is used off-label for IVF pituitary suppression (where a 2001 meta-analysis of 9 RCTs found outcomes equivalent to other GnRH agonists). The honest caveats are class-level: the expected initial estrogen or testosterone 'flare' during the first 1–2 weeks, reversible bone mineral density loss during extended therapy (which is the principal reason FDA labeling limits endometriosis treatment to 6 months without add-back), and the predictable menopausal symptom burden of profound estrogen suppression. Route-specific caveats unique to nafarelin include a higher rate of nasal irritation and rhinitis, the need for careful spray technique, potential absorption disruption by upper respiratory infections or decongestant use, and relatively low (~2–3%) bioavailability requiring twice-daily dosing. Selection between nafarelin and a depot agonist (leuprolide, triptorelin, goserelin) is typically driven by patient preference for non-injectable administration, pediatric use considerations, and clinician familiarity — efficacy is essentially equivalent.
History & Discovery
Nafarelin was developed by Syntex Research in the early 1980s as part of the intensive pharmaceutical-industry search for clinically superior GnRH superagonists that followed Andrew Schally and Roger Guillemin's Nobel Prize-winning elucidation of native GnRH structure (1977 Nobel Prize in Physiology or Medicine). The defining structural innovation in nafarelin was the 3-(2-naphthyl)-D-alanine substitution at position 6 — a highly lipophilic, bulky unnatural amino acid that simultaneously increased GnRH receptor binding affinity (roughly 200-fold over native GnRH) and conferred the membrane permeability needed for practical nasal mucosal absorption. The latter property turned out to be the commercially and clinically distinguishing feature of the molecule: while leuprolide, triptorelin, goserelin, and buserelin were developed into injectable depot formulations, nafarelin was uniquely positioned for twice-daily intranasal administration. Syntex filed the New Drug Application for Synarel (nafarelin acetate 2 mg/mL nasal spray) in November 1988. The FDA Fertility and Maternal Health Drug Products Advisory Committee recommended approval by a 9-0 vote (one abstention) in April 1989, and Synarel received final FDA approval on February 13, 1990 as a '1B' (therapeutic advantage over existing treatments) designation for management of pelvic pain and lesion reduction associated with endometriosis. The pivotal evidence base was a multicenter double-blind RCT (n=213) comparing intranasal nafarelin to oral danazol, published in 1988. Synarel was the first new endometriosis treatment to enter the US market in 14 years. FDA approval for central precocious puberty followed in 1992, extending nafarelin into pediatric endocrinology practice where the non-injectable route offered a meaningful usability advantage for young patients on multi-year therapy. Syntex was acquired by Roche in 1994, and the Synarel franchise subsequently moved through ownership changes to Pfizer, which markets the product in the US today. Generic nafarelin acetate nasal spray has not become widely available in the US market, and Synarel remains a relatively low-volume specialty product compared with the depot GnRH agonist franchises (Lupron, Trelstar, Zoladex). Clinically, nafarelin occupies a stable niche for patients who prefer non-injectable GnRH agonist therapy and for pediatric precocious puberty cases where family preference and adherence favor intranasal administration.
How It Works
Nafarelin is the nose-spray version of the prostate-cancer and endometriosis drug class. It mimics the brain's reproductive hormone (GnRH), but so continuously that the pituitary receptors shut down. That cuts LH and FSH, which cuts estrogen and testosterone — useful for endometriosis, fibroids, and precocious puberty. Intranasal delivery means no injections, but requires twice-daily dosing to maintain suppression.
Nafarelin acetate is a nonapeptide with the sequence pGlu-His-Trp-Ser-Tyr-D-2-Nal-Leu-Arg-Pro-Gly-NH2, with the 3-(2-naphthyl)-D-alanine substitution at position 6 providing both enhanced GnRH receptor binding affinity (roughly 200-fold over native GnRH) and the lipophilicity needed for effective nasal mucosal absorption. Peak serum concentration is reached 10–40 minutes after intranasal administration, bioavailability averages 2.8% (range 1.2–5.6%), and the serum half-life is approximately 3 hours. Nafarelin is ~80% plasma-protein-bound, cleared by peptidase-mediated proteolytic degradation (not CYP-metabolized), and excreted primarily in urine. Six metabolites have been identified; the major one is a Tyr-D(2)-Nal-Leu-Arg-Pro-Gly-NH2 (5–10) fragment. Acute administration triggers LH and FSH release via Gq-coupled GnRH receptor signaling. Twice-daily continuous exposure produces pituitary GnRH receptor internalization, uncoupling from phospholipase C signaling, and transcriptional downregulation — the class 'desensitization' effect. Medical castration levels of estrogen or testosterone are typically reached by 2–4 weeks of continuous twice-daily use.
Evidence Snapshot
Human Clinical Evidence
Extensive. FDA-approved since 1990 for endometriosis and since 1992 for central precocious puberty. Multiple head-to-head randomized trials against danazol, leuprolide, buserelin, and triptorelin across endometriosis, fibroid, and IVF indications.
Animal / Preclinical
Comprehensive. GnRH receptor desensitization and HPG axis suppression are thoroughly characterized across the class.
Mechanistic Rationale
Very strong. GnRH receptor pharmacology, pituitary desensitization kinetics, and intranasal pharmacokinetics (10–40 min Tmax, ~2.8% bioavailability, ~3 hr half-life) are well-established.
Research Gaps & Open Questions
What the current literature has not yet settled about Nafarelin:
- 01Head-to-head comparative effectiveness of intranasal nafarelin versus depot leuprolide or triptorelin in endometriosis pain outcomes beyond 6 months — longer-term comparative data are limited, and real-world adherence differences between twice-daily nasal and monthly/3-monthly depot administration are imperfectly characterized.
- 02Optimal add-back regimens for extended or repeat-course nafarelin therapy — progestin-only and combined estrogen-progestin add-back have both been studied, but complete prevention of bone mineral density loss is not reliably achieved; the best regimen for patients requiring prolonged treatment remains debated.
- 03Nafarelin for adenomyosis specifically — clinical experience suggests benefit, but high-quality RCT evidence for adenomyosis as a distinct indication from endometriosis is limited.
- 04Long-term bone health outcomes after pediatric nafarelin treatment for central precocious puberty — adult BMD and fracture-risk outcomes after childhood GnRH agonist therapy continue to accumulate in registry data.
- 05Generic and biosimilar availability — the absence of a widely available generic nafarelin acetate nasal spray in the US market is economic and regulatory rather than scientific, but it affects access and has not been resolved.
- 06Route comparison studies in pediatric precocious puberty — the relative long-term impact on adult height, BMD, and psychosocial outcomes of intranasal nafarelin versus depot histrelin implant or leuprolide depot in pediatric patients is an ongoing area of comparative study.
- 07Nafarelin pharmacokinetic variability between patients — individual variation in nasal bioavailability (labeled range 1.2–5.6%) is substantial, but clinical tools for identifying patients who may need dose escalation or a switch to injectable therapy are not standardized.
Forms & Administration
Intranasal spray only. Synarel is supplied as a metered-dose nasal spray delivering 200 mcg per spray. Standard endometriosis dose: 200 mcg once in each nostril morning and evening (total 400 mcg/day, dose can be increased to 800 mcg/day in patients with persistent regular menstruation after 2 months). Central precocious puberty: 400 mcg (2 sprays of 200 mcg) in each nostril morning and evening (total 1600 mcg/day). Technique matters — head tilted slightly forward, spray without sniffing forcefully. Avoid topical decongestant sprays within 2 hours of dosing. All GnRH agonist therapy should only be initiated and monitored under the guidance of a qualified clinician.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Endometriosis (adult women): 200 mcg (one spray) in one nostril in the morning and 200 mcg in the other nostril in the evening — total daily dose 400 mcg. Alternating nostrils morning and evening. If regular menstruation persists after 2 months of therapy, the dose may be increased to 800 mcg/day (one spray in each nostril morning and evening). Central precocious puberty (children age 2 and older): 1600 mcg/day total, delivered as 2 sprays (400 mcg) in each nostril in the morning and 2 sprays in each nostril in the evening. The higher pediatric dose reflects the need for complete pituitary suppression in the face of physiologic pubertal drive.
Frequency
Twice daily (every ~12 hours), morning and evening. Consistent timing matters because the drug's ~3 hour serum half-life means suboptimal dosing interval can allow LH/FSH breakthrough.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Endometriosis: FDA-labeled for a recommended duration of 6 months. Retreatment is not routinely recommended because BMD loss accrues with repeated courses; if retreatment is considered, it should include monitoring of bone density. Central precocious puberty: treatment is continued until the age at which puberty is physiologically appropriate (typically discontinued around ages 11–12 in girls and 12–13 in boys, individualized to the patient). The reversibility of GnRH agonist effects after discontinuation allows normal pubertal progression.
Protocol Notes
Proper nasal spray technique is essential: the patient should tilt the head slightly forward, insert the spray tip into the nostril, and breathe gently through the nose during the spray — forceful sniffing can deposit drug in the throat rather than on nasal mucosa, reducing absorption. Avoid topical decongestant nasal sprays within 2 hours of the nafarelin dose; decongestant-induced vasoconstriction can reduce mucosal uptake. Nasal irritation, mild sinusitis, and rhinitis are common route-specific side effects that usually do not require discontinuation. Patients with chronic rhinitis, structural nasal abnormalities, or frequent upper respiratory infections may be better served by an injectable GnRH agonist with more consistent bioavailability. The expected GnRH agonist 'flare' — transient increase in LH, FSH, estradiol, and initial symptom worsening during the first 1–2 weeks — applies to nafarelin as it does to the injectable agonists. For endometriosis, starting therapy between days 2 and 4 of menstruation is standard. Patients should be counseled that hot flashes, vaginal dryness, decreased libido, mood changes, and headache are common and expected consequences of profound estrogen suppression. Bone mineral density loss is the principal long-term safety concern. In 6-month endometriosis trials, nafarelin at 400 mcg/day produced roughly 6% loss of vertebral trabecular bone. This loss is largely but not completely reversible after discontinuation — small residual deficits have been documented in some patients at 6-month post-treatment follow-up. The FDA-labeled 6-month maximum and the general recommendation against routine retreatment reflect this concern. Hormonal add-back therapy (norethindrone and related progestins, or low-dose estrogen-progestin combinations) is used in extended or repeated treatment courses to mitigate bone loss and vasomotor symptoms, though evidence of partial rather than complete protection has been documented in controlled trials. Effective non-hormonal contraception is required during treatment — nafarelin does not reliably prevent ovulation during the first 1–2 weeks of therapy, and pregnancy exposure can cause fetal harm.
Nafarelin (Synarel) is FDA-approved for endometriosis in adult women and for central precocious puberty in children age 2 and older. Off-label use for IVF pituitary suppression and uterine fibroid preoperative management is common internationally and in specialist US practice. Use outside approved indications requires specialist supervision and should include monitoring of bone density and endocrine status.
Timeline of Effects
Onset
Nafarelin is absorbed rapidly after intranasal administration, with peak serum concentration reached 10–40 minutes after a dose. The initial GnRH agonist 'flare' — increased LH, FSH, and consequent rise in estradiol (or testosterone in men treated off-label) — occurs over the first 7–14 days. Pituitary desensitization develops over the next 2–4 weeks, and medical castration-level estrogen (or testosterone) is typically achieved by weeks 3–4 with consistent twice-daily dosing. Symptom response in endometriosis — reduction in pelvic pain, dysmenorrhea, and dyspareunia — becomes evident by 4–8 weeks. In central precocious puberty, suppression of pubertal progression, stimulated LH response, and bone age advancement is observed over the first months of consistent therapy.
Peak Effect
Maximal hormonal suppression is maintained throughout the treatment period as long as twice-daily dosing is consistent and nasal absorption is not compromised. Amenorrhea develops in the majority of women treated for endometriosis, typically by months 2–3. In pediatric precocious puberty, sustained suppression of stimulated LH, slowing of bone age progression, and deceleration of breast and genital development are maintained across the months-to-years of therapy. Bone mineral density loss accumulates with continued therapy, with measurable deficits by 6 months and the principal reason for the 6-month FDA-labeled treatment limit.
After Discontinuation
Pituitary function and gonadal hormone production recover gradually after nafarelin discontinuation. Menstrual cycles typically return within 4–10 weeks of stopping treatment, with fertility restoration following. In central precocious puberty, reversal of pituitary suppression and normal pubertal progression has been documented in essentially all children for whom 1-year post-treatment follow-up was available, with return of menses, pubertal gonadotropin levels, and secondary sexual development. Bone mineral density recovers substantially over 6–24 months after therapy, though small residual deficits have been documented in some patients — this is distinct from the depot GnRH agonists only in that the shorter half-life of intranasal nafarelin means washout and recovery begin immediately on discontinuation, whereas depot formulations continue to release drug for weeks to months after the last injection.
Common Questions
Who Nafarelin Is NOT For
- •Pregnancy — nafarelin can cause fetal harm; effective non-hormonal contraception is required during therapy and pregnancy must be excluded before initiation.
- •Breastfeeding — not recommended; nafarelin excretion in human milk is not fully characterized and GnRH suppression in a nursing infant is not an acceptable exposure.
- •Known hypersensitivity to nafarelin or to GnRH or any GnRH analog (cross-reactivity is possible).
- •Undiagnosed abnormal vaginal bleeding — should be evaluated before initiating therapy for endometriosis.
- •Severe, symptomatic nasal mucosa disease — chronic severe rhinitis, significant nasal polyposis, or structural nasal deformities that would impair reliable mucosal absorption are relative contraindications; injectable GnRH agonist therapy may be preferable.
- •Pre-existing severe osteoporosis without bone-protective co-therapy — relative contraindication; bone protection (bisphosphonate, denosumab, or hormonal add-back) should accompany extended or repeated nafarelin therapy in at-risk patients.
- •Pediatric use outside central precocious puberty — use in children outside the approved precocious puberty indication is not established.
- •Patients unable to reliably perform twice-daily nasal spray administration — the twice-daily dosing requirement is more demanding than depot injections and poor adherence produces LH/FSH breakthrough and loss of therapeutic benefit.
Drug & Supplement Interactions
Nafarelin has a relatively limited classical pharmacokinetic drug-interaction profile because peptide proteolytic clearance does not engage CYP-mediated metabolism. The clinically important interactions are either pharmacodynamic (related to HPG-axis suppression) or route-specific (related to intranasal absorption). Topical nasal decongestants (oxymetazoline, phenylephrine, pseudoephedrine nasal sprays): vasoconstrictor-mediated reduction in nasal mucosal blood flow can reduce nafarelin absorption. Labeling recommends separating decongestant nasal spray use from nafarelin administration by at least 2 hours, or avoiding concurrent use where possible. Oral decongestants have less clear interaction magnitude but the same theoretical concern. Intranasal corticosteroids (fluticasone, mometasone, budesonide nasal sprays): commonly used for chronic rhinitis. Limited direct interaction data; separation of doses and attention to symptom response during initiation is reasonable. Upper respiratory infections, allergic rhinitis flares, and sinusitis: not drug interactions per se, but clinically important situations where mucosal absorption can be reduced. Patients should be counseled that significant nasal congestion may transiently reduce drug effect. Hormonal add-back therapy (norethindrone acetate, low-dose estrogen-progestin combinations): deliberately combined during extended or repeated nafarelin therapy to mitigate bone loss and vasomotor symptoms. The interaction is intended; complete prevention of BMD loss is not reliably achieved. QT-prolonging medications: GnRH agonists can prolong QT interval; combination with other QT-prolonging agents (Class IA and III antiarrhythmics, certain antiemetics, fluoroquinolones, methadone) warrants ECG monitoring in at-risk patients. Hyperprolactinemia-associated medications (certain antipsychotics, metoclopramide): can theoretically interfere with HPG-axis dynamics; clinical significance during established nafarelin suppression is modest. Combined hormonal contraceptives: nafarelin is not a reliable contraceptive during the first 1–2 weeks of therapy. Non-hormonal contraception should be used. Hormonal contraception can interfere with the intended treatment effect by adding exogenous estrogen and is generally not co-administered during nafarelin endometriosis therapy unless as a planned add-back regimen.
Safety Profile
Common Side Effects
Cautions
- • Initial estrogen/testosterone flare during the first 1–2 weeks
- • Bone mineral density loss with extended therapy — 6-month FDA limit without add-back
- • Not for use in pregnancy — effective non-hormonal contraception required during therapy
- • Nasal absorption can be reduced by upper respiratory infections, rhinitis, or concurrent nasal decongestant use
- • Twice-daily dosing discipline matters — missed doses allow LH/FSH breakthrough
What We Don't Know
Well-characterized safety profile with more than 35 years of clinical use since 1990 FDA approval. Route-specific nasal-mucosa effects are well-studied. Long-term pediatric outcomes from central precocious puberty treatment are reassuring in registry data but continue to accumulate.
Legal Status
United States
Nafarelin (Synarel) is FDA-approved (initial approval February 13, 1990) for management of pelvic pain and lesion reduction in endometriosis in adult women, and (1992) for central precocious puberty in children age 2 and older. It is a prescription-only specialty medication, not a controlled substance, marketed in the US by Pfizer. Synarel is supplied as a 2 mg/mL metered-dose nasal spray delivering 200 mcg per spray. A generic nafarelin acetate nasal spray has not become widely established in the US market.
International
Approved across major markets (EMA, MHRA, Health Canada, Australia TGA, Japan) for endometriosis and central precocious puberty under the Synarel trade name and regional equivalents. Off-label use for uterine fibroids and IVF pituitary suppression is common internationally. The intranasal delivery route distinguishes nafarelin from leuprolide (Lupron), goserelin (Zoladex), and triptorelin (Decapeptyl) in most markets, where depot GnRH agonists dominate the therapeutic class.
Sports & Competition
Nafarelin and other GnRH agonists are listed on the WADA Prohibited List under S4 (Hormone and Metabolic Modulators), prohibited for any use in male athletes (S4.3 historically and the current S4 framework for pituitary hormone-releasing factors). The classification reflects use in 'post-cycle therapy' contexts following anabolic-androgenic steroid administration. Therapeutic use for endometriosis, central precocious puberty, or other approved indications under appropriate Therapeutic Use Exemption is permitted; non-therapeutic use is prohibited in and out of competition.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Nafarelin is a different kind of drug from leuprolide because it's a nasal spray.
Reality
They are both GnRH agonists in the same pharmacological class, working by the same desensitization mechanism — continuous GnRH receptor stimulation that downregulates pituitary gonadotropes and shuts down LH/FSH. The difference is delivery route: nafarelin is intranasal twice daily, leuprolide is intramuscular or subcutaneous depot at 1- to 6-month intervals. Clinical efficacy across the class is essentially equivalent. Selection is driven by patient preference, adherence, pediatric considerations, and clinician familiarity.
Myth
Because nafarelin is a nasal spray, it avoids the systemic side effects of injectable GnRH agonists.
Reality
Nafarelin produces the same systemic side effects as depot GnRH agonists — hot flashes, vaginal dryness, decreased libido, mood changes, and bone mineral density loss — because it produces the same systemic hormonal effect (castrate-level estrogen or testosterone). Route of administration does not meaningfully change the systemic profile. In addition, nafarelin has route-specific side effects (nasal irritation, rhinitis) that the injectable agents do not.
Myth
Bone loss on nafarelin is fully reversible so it's not really a concern.
Reality
Bone mineral density loss during 6 months of nafarelin at 400 mcg/day is meaningful — roughly 6% loss of vertebral trabecular bone. Recovery after discontinuation is substantial but not complete. Studies have documented small residual BMD deficits at 6 months post-treatment, and this is the principal reason FDA labeling limits continuous use to 6 months without add-back and cautions against routine retreatment. The concern is real enough to shape treatment planning.
Myth
Nafarelin can be used indefinitely for endometriosis or fibroids.
Reality
The FDA-labeled continuous-use limit is 6 months. Retreatment is not routinely recommended because BMD loss accrues across repeated courses. Extended use requires hormonal add-back therapy and bone density monitoring. Patients needing long-term hormonal management of endometriosis are typically transitioned to combined hormonal contraception, progestin monotherapy, or dienogest after the initial GnRH agonist course.
Myth
Missing a dose of nafarelin doesn't matter because it's a long-acting drug.
Reality
Nafarelin has a ~3 hour serum half-life, which is why it requires twice-daily dosing. Missing doses allows LH/FSH breakthrough and loss of pituitary suppression. This is the opposite of depot GnRH agonists (leuprolide depot, triptorelin depot), which maintain continuous drug exposure for 1–6 months from a single injection. Adherence discipline is a meaningful difference between nasal and depot GnRH agonist therapy.
Published Research
28 studiesA randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan
Efficacy of nafarelin in assisted reproductive technology: a meta-analysis
Meta-analysis of 9 RCTs (n=1,014 women treated with nafarelin) for IVF pituitary suppression, establishing equivalence to buserelin, triptorelin, and leuprolide on pregnancy rates per embryo transfer, fertilization rates, and oocyte recovery. Anchors nafarelin's role in ART.
Treatment of endometriosis with a decreasing dosage of a gonadotropin-releasing hormone agonist (nafarelin): a pilot study with low-dose agonist therapy ("draw-back" therapy)
A comparison of three gonadotrophin-releasing hormone analogues in an in-vitro fertilization programme: a prospective randomized study
Therapeutic efficacy and bone mineral density response during and following a three-month re-treatment of endometriosis with nafarelin (Synarel)
Use of nafarelin versus placebo after reductive laparoscopic surgery for endometriosis
Nafarelin vs. leuprolide acetate depot for endometriosis. Changes in bone mineral density and vasomotor symptoms. Nafarelin Study Group
Head-to-head RCT comparing intranasal nafarelin against leuprolide depot in endometriosis, documenting comparable efficacy with distinct BMD and vasomotor symptom profiles — the core evidence for selecting between nasal and depot GnRH agonist therapy.
A double-blind randomized study of the treatment of endometriosis with nafarelin or nafarelin plus norethisterone
Retreatment with nafarelin for recurrent endometriosis symptoms: efficacy, safety, and bone mineral density
Reduction of bone mineral density by gonadotropin-releasing hormone agonist, nafarelin, is not completely reversible at 6 months after the cessation of administration
Key evidence that 6-month nafarelin-induced BMD loss is not fully reversible by 6 months after discontinuation — the single reference most often cited for the FDA-labeled 6-month treatment limit and the general caution against routine retreatment.
A prospective randomized comparison of two gonadotrophin-releasing hormone agonists, nafarelin acetate and buserelin acetate, in in-vitro fertilization-embryo transfer
Nafarelin therapy in endometriosis: long-term effects on bone mineral density
Postsurgical medical treatment of advanced endometriosis: results of a randomized clinical trial
A prospective randomized single-blind comparative trial of nafarelin acetate with buserelin in long-protocol gonadotrophin-releasing hormone analogue controlled in-vitro fertilization cycles
Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain
Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial
Pivotal multicenter double-blind RCT (n=213) comparing intranasal nafarelin (400 or 800 mcg/day) against oral danazol (800 mg/day) for 6 months in laparoscopically confirmed endometriosis. More than 80% in each group had reduction in disease extent. A foundational reference for nafarelin's FDA approval in endometriosis.
Intranasal nafarelin: an LH-RH analogue treatment of gonadotropin-dependent precocious puberty
Early clinical study establishing intranasal nafarelin efficacy in gonadotropin-dependent central precocious puberty — the foundational evidence for the 1992 pediatric FDA approval.
Dose-dependent inhibition of pituitary-ovarian function during administration of a gonadotropin-releasing hormone agonistic analog (nafarelin)
Clinical experience treating endometriosis with nafarelin
Role of nafarelin in the management of endometriosis
A comparison of nafarelin acetate and danazol in the treatment of endometriosis
Nafarelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions
Comprehensive 1990 Drugs-journal review of nafarelin pharmacology, pharmacokinetics, and clinical applications — the definitive single-reference overview of the drug written at the time of FDA approval.
Nafarelin in the treatment of pelvic pain caused by endometriosis
Efficacy and safety of nafarelin in the treatment of endometriosis
Effect of nafarelin on uterine fibroids measured by ultrasound and magnetic resonance imaging
Nafarelin versus leuprolide in ovulation induction for in vitro fertilization: a randomized clinical trial
A randomized double blind placebo controlled trial of the effects on bone metabolism of the combination of nafarelin acetate and norethisterone
Clinical use of nafarelin in the treatment of leiomyomas: a review of the literature
Quick Facts
- Class
- GnRH Agonist
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Apr 2026
- Citations
- 28PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.